ArticleBMC pediatrics2025
Lessons learned from the outbreak: the use of fomepizole in children with acute kidney injury due to ethylene glycol/diethylene glycol poisoning.
Article in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ethylene glycol (EG) and diethylene glycol (DEG) intoxication, defined as > 20 mg/dL in plasma, can cause severe morbidity and mortality due to their metabolism into toxic metabolites via alcohol dehydrogenase (ADH). In August 2022, Indonesia experienced a surge in acute kidney injury (AKI) cases in children, initially misdiagnosed as multisystem inflammatory syndrome in children (MIS-C). Following a World Health Organization (WHO) alert on EG/DEG-related AKI in Gambia, toxicology screening confirmed EG/DEG contamination in syrup-based medications. This study evaluates the efficacy of fomepizole in treating 19 pediatric patients with EG/DEG intoxication. All patients received fomepizole based on American Academy of Clinical Toxicology (AACT) guidelines, with additional hemodialysis in severe cases. Laboratory assessments revealed metabolic acidosis, elevated urea and creatinine levels, and hepatic dysfunction. Fomepizole administration led to significant renal function improvement, with 14 patients recovering and five fatalities (mortality rate: 26.3%). While fomepizole showed transient hepatotoxic effects, overall hepatic function improved. Early recognition of EG/DEG intoxication is critical, as clinical symptoms may not follow a predictable progression. Prompt administration of fomepizole significantly reduces morbidity and mortality, making it an essential intervention for EG/DEG poisoning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.